Madrid-based Buenavista Equity Partners and Columbus Venture Partners have closed the €100 million BV Healthcare Growth Invest Fund I, with plans to continue fundraising until reaching a hard cap of €150 million. The fund aims to support 10-12 healthcare companies, primarily in Spain.
- Founded in 1996 by Enrique Centelles and Felix Guerrero, Buenavista Equity Partners manages over €1 billion across various Private Equity, Infrastructure, and Venture Capital funds. Columbus Venture Partners, established in 2015 by Javier Garcia, is a Madrid-based investment firm focused on early-stage opportunities in the life sciences sector.
- The two firms have partnered to launch a new healthcare fund, targeting investments in 10-12 healthcare companies, primarily in Spain. The fund aims to invest up to €15 million per company, addressing the growing demand for growth capital in the healthcare sector and positioning the BV Healthcare Growth Invest Fund I to capitalize on emerging opportunities.
- The fund will focus on a broad range of sectors, including pharmaceuticals and biotech, diagnostic solutions, precision medicine, medical equipment, AI & big data, digital therapies, industrial production scale-up projects, scientific services (CRO, CDMO), and healthcare services.
- Already, the fund has supported Syngoi Technologies, a Spanish biotech startup specializing in the cost-effective and scalable production of synthetic DNA using patented cell-free methods.
"We are very excited to announce the launch of this new fund dedicated exclusively to the healthcare sector. Buenavista is entering a new phase of growth, with a strong commitment to a sector where we are already present, and which displays great opportunities," Claims Nuria Osés, Partner and head of the Healthcare strategy at Buenavista.
- The new fund has received backing from the Centre for Technological Development and Innovation (CDTI), which has allocated up to €58 million through its Innvierte Programme, a co-investment initiative designed to support the development of innovative therapies and drug advancements.
"Given the lack of financing by specialised investors for this type of high-growth medical companies in Spain and in the European market, we believe that this fund fills a great gap in an area of great economic and social relevance," Managing Partner and co-founder of Columbus Venture Partners, Damià Tormo, commented.
